The modern biomedical research enterprise is a complex ecosystem, encompassing topics as diverse as social psychology and physical chemistry. Optimizing the management of biomedical research projects, including the \>70,000 awards made by the National Institutes of Health (NIH) each year, requires a deep understanding of this complexity on both a qualitative and quantitative level. Administrators in academia face a similar challenge as they pursue the most promising opportunities when hiring faculty and making capital investments. As decision makers have increasingly turned to metrics for assistance in pruning these large and elaborate decision trees, the ongoing use of inadequate metrics has fomented numerous protests ([@B60]; [@B19]; [@B17]; [@B47]; [@B7]; [@B12]; [@B22]; [@B54]; [@B2]; [@B15], [@B16]; [@B14]; [@B18]; [@B29]; [@B49]; [@B4]; [@B10]; [@B26]; [@B5]; [@B8]; [@B13]; [@B32]). Widespread concern about the use of flawed metrics derives not only from an awareness of their limitations but also from the reality that careers, and ultimately perhaps the scientific enterprise at large, are at stake.

GETTING BEYOND JOURNAL IMPACT FACTOR: VALIDATED METRICS CAN MAKE A POSITIVE CONTRIBUTION
========================================================================================

The Journal Impact Factor (JIF) is one example of a statistically flawed measurement of citation activity that has seen broad adoption over the past few decades as a proxy for both the quality and impact of research publications. The technical shortcomings of JIF as a metric have been amply documented ([@B50]; [@B56]; [@B42], [@B43]; [@B1]; [@B12]; [@B30]; [@B40]; [@B51]; [@B61]; [@B5]; [@B8]; [@B13]; [@B28]; [@B32]). Most importantly, JIF is mathematically invalid because it is calculated as the *average* number of times the entire collection of articles in a given journal is cited, but in reality, citations follow a *log-normal* rather than a Gaussian distribution ([@B57]). This means that two articles in the same journal---indeed, even in the same issue of that journal---can differ in citation activity by up to three logs. Field-specific differences, both in citation activity and in access to high-profile publication venues, further invalidate the use of JIF to assess the influence of a scientist's research at the article level. JIF is also of little or no value in comparing research outputs of developed and developing nations or different types of institutions because meaningful apples-to-apples assessments require an article-level metric that includes a benchmarking step.

That JIF is an inappropriate tool for selecting winners in the intense competition for status and resources is highlighted by the observation that everything published in journals with a high JIF (≥28), taken together, accounts for only a small fraction of the most influential articles ([@B6]; [@B28]). (Note that influence, not impact or quality, is what citation activity measures; more about that later.) Awareness of the flaws in JIF and the accompanying prisoner's dilemma ([@B3]; [@B24]), in which scientists failing to pursue publication in high-JIF journals run the very real risk of being outcompeted by their peers, date at least as far back as 1997, and so do suggestions for combatting what was already by then a growing problem ([@B56]). Despite this long-standing criticism, JIF has persisted in the absence of a quantitative approach that is a collectively agreed-upon alternative.

What method could replace JIF as a means of evaluating scientific productivity? Some have argued that the only acceptable solution is a return to the tradition of making career-determining judgments by relying exclusively on expert opinion, supplemented in the time-honored manner by peer recommendations, informal discussions, and other subjective criteria. Although this would seem to be an ideal solution, there are many circumstances in which it is unworkable in practice. Decision makers sometimes lack the bandwidth to review thoroughly the entire corpus of publications relevant to a given decisional task, whether they are considering a large cohort of applicants for an open faculty position, developing a funding opportunity announcement, or reviewing applications in a peer review meeting. Exponential expansion of the number of entries in PubMed over the past few decades, culminating in the current rate of more than one million publications per year ([Figure 1](#F1){ref-type="fig"}), can represent a serious challenge to experts who wish to rely exclusively on manual inspection when assessing contributions from a group of applicants to their chosen fields of research. This is especially true because many of these same experts, in addition to judging grant applications and vetting potential future colleagues, are regular reviewers of submissions to a variety of journals and conferences and are also occasionally called upon to review promotion and tenure dossiers. Indeed, the time and effort occupied by this portion of the typical workload of principal investigators, which makes a marginal contribution to their own career advancement and is done out of a sense of duty, may have helped to stimulate the widespread adoption of JIF as a proxy for quality.

![Exponential expansion of the number of articles in PubMed (1982--2015). (A) Blue-filled circles, all articles; pink-filled circles, NIH-funded articles. (B) Percentage of articles in PubMed authored by NIH awardees.](1401fig1){#F1}

Beyond these logistical realities, exclusive reliance on expert opinion has its own methodological drawbacks. Although metrics should never be used as a substitute for human judgment, the latter is far from perfect and can succumb to a wide variety of conscious and subconscious biases (for an excellent discussion of bias in peer review, see [@B37]). In addition to gender bias---the more favorable treatment of men in peer review ([@B64]; [@B11]; [@B33]; [@B59]; [@B38]; [@B46])---potential biases include prestige bias---the "benefit of the doubt" given to scientists who have gained a cumulative advantage by benefiting from greater and greater prestige as they disproportionately garner a larger and larger share of limited resources (sometimes called the "Matthew effect"; [@B39]; [@B48]; [@B9]); affiliation bias---favoritism based on semiformal or informal relationships between applicants and reviewers that are not addressed by conflict of interest rules ([@B64]; [@B53]); content-based bias---preference for those who study similar problems and/or belong to a similar "school of thought" ([@B27]; [@B58]; [@B36]); and confirmation bias---the tendency to favor ideas and/or evidence that reinforces, rather than challenges, one's views ([@B23]; [@B44]). Well-designed and thoroughly tested metrics have the potential to expose bias where it exists and may therefore ultimately play an important role in assisting experts who might otherwise, however unintentionally, continue to apply those biases systematically when reviewing the work of others. Ironically, one of the most commonly held prestige biases might be the outsized esteem conferred on those who publish in high-JIF journals at the expense of scientists who publish work of equal or greater value elsewhere ([@B22]; [@B25]).

A MATHEMATICALLY SOUND, VALIDATED ALTERNATIVE: THE RELATIVE CITATION RATIO
==========================================================================

As captured in the aphorism "you can't replace something with nothing," reliance on JIF as a proxy for quality might continue unless decision makers are convinced that there is a valid alternative. At the NIH, we therefore sought to develop such an alternative. Before any new metric can serve in this role, it must at a minimum be both statistically and bibliometrically sound and lend itself to careful interpretation within a broader context. The only valid way to assess the influence of publications is at the article level. Replacing journal-level with article-level assessment would place the many highly influential articles that appear in JIF \< 28 journals on an equal footing with those in JIF ≥ 28 journals.

To judge fairly whether an individual article is well or poorly cited, it is necessary to identify other works in the same field with which it can be compared. Our metric, the Relative Citation Ratio (RCR), uses an article's co-citation network---that is, the other articles that appear alongside it in reference lists---to define its unique and customized field. An important advantage of this method of field normalization is that it leverages the collective experience of publishing scientists, who are the best judges of what relevance one article has to another. RCR also time-normalizes by considering citation rates rather than raw citation counts and, unlike any other available metric, uses a customizable benchmark to allow comparisons between specific peer groups ([Figure 2](#F2){ref-type="fig"}; [@B28]). Extensive testing and validation has demonstrated that the RCR method meets the requirements that should be demanded of any metric before it is adopted as a component in data-driven decision making: RCR values are calculated in a transparent fashion, benchmarked to peer performance, correlated with expert opinion, scalable from small to large collections of publications, and freely accessible (publicly available through our web-based iCite tool (icite.od.nih.gov; [@B28]), with open-source code (<https://github.com/NIHOPA/Relative-Citation-Ratio-Manuscript>).

![Using co-citation networks to calculate RCR. (A) Schematic of a co-citation network. The red circle represents a reference article (RA); blue circles represent articles citing the RA, and orange circles represent articles cited by the RA. The co-citation network of the RA is represented in green and is defined as the collection of articles cited by articles that also cite the RA. (B) Examples of co-citation network growth over time. The growth of the networks of articles co-cited (green circles) in articles that also cite representative RAs (red circles) published in 2006 (three examples from top to bottom). From left to right in each row, the co-citation networks expand between 2006 and 2011. (C) Normalizing article citation rates to calculate RCR. Expected citations rates are generated by benchmarking NIH-funded article citation rates to the citation rates for articles in their co-citation network (field citation rate). RCR is calculated by dividing the article citation rate of each article by its expected citation rate. This figure was adapted from [Figures 1](#F1){ref-type="fig"} and [3](#F3){ref-type="fig"} of [@B28]).](1401fig2){#F2}

Because even thoroughly tested and validated metrics can be misused, it is exceedingly important to define what they do and do not measure. As currently applied to scientific publications, it is a daunting challenge to measure, let alone to predict, the impact of specific advances in knowledge. For this reason, we do not say that RCR values measure the *impact*, but rather the *influence* of each article relative to what is expected, given the scope of its scientific topic. Redefining citations as a measure of influence is important because it addresses valid and often-expressed concerns about the variety of ways in which authors cite the work of others; examples include citing a report that the citer disagrees with or considers flawed, adding citations to please a journal editor ([@B65]), and citing more recent articles or reviews rather than the original report of a scientific advance. The concept of influence, broader and more neutral than the lens through which citations are now commonly viewed, also provides important context for understanding how RCR should be interpreted---as an indicator of the value that the relevant academic audience places on transmission of the information contained in one or more publications.

It is also important to keep in mind that citations follow a power law or log-normal distribution ([@B62]), meaning that as a researcher explores the literature, some of the articles that match his or her area of interest are far more visible than others. Consequently the choice of which article to cite is at least partly informed by the choices that other researchers previously made. The results of a landmark study on the relationship between quality and success in a competitive market illustrate the importance (and potential for bias) that is inherent in these early choices; winners are neither entirely random nor entirely meritocratic, and success is strongly influenced by intangible social variables ([@B52]). This means that, although highly influential publications are as a rule important and of high quality, the converse is not necessarily true. RCR is therefore designed to contribute to decision making, not as a substitute for human judgment, but as one component of a multifaceted approach that places expert opinion at the center of assessments of scientific productivity. As we say at the NIH, bodies of work that have higher or lower RCR values than the benchmarked median value of 1.0 should be "flagged for inspection" and interpreted in the broader context of a diverse set of parameters. Note also that, given the inherent noise and intangible variables that affect the output of individuals, NIH decision makers are using RCR and other parameters only to measure the outputs of groups of researchers, not to assess individuals for the purpose of making funding decisions.

NEXTGEN PORTFOLIO ANALYSIS: USING RCR AS ONE COMPONENT OF A DIVERSE METRIC
==========================================================================

Others have also highlighted the value of developing multifaceted assessments. For example, [@B29]) incorporated just such a diverse set of parameters into a metric that they termed PQRST (productivity, quality, reproducibility, sharing of data and other resources, and translation. Of course, productivity goes beyond merely totting up the number of article in a portfolio. Therefore one way to adapt their innovative idea is to replace P with I (influence), yielding IQRST; RCR (or weighted RCR; [@B28]) can be used as the I component of the metric. Certain aspects of R and S might also be amenable to quantitation ([@B55]; [@B45]). By its very definition, Q requires a qualitative (i.e., human) judgment. T, for translation, can also be measured by quantifying citations by clinical trials or guidelines, with two caveats. First, several years must elapse to obtain a sufficient signal. Second, this is a measure of direct translation; it does not detect the equally important occurrences of extended translation, defined as a series of citations that connect basic research with impact on human health. For this reason, [@B63]) proposed the "triangle of biomedicine" to identify and visualize extended translation ([Figure 3](#F3){ref-type="fig"}). We are working to adapt this framework into a tool to analyze a selected portfolio of articles and track its progress toward translation. Development of this and other metrics can contribute to NextGen data-driven decision making by funders of biomedical research.

![Capturing indirect translation with Griffin Weber's triangle of biomedicine. Sample visualization of indirect translation leading to the development of Voraxaze, a Food and Drug Administration--approved drug used to treat toxic plasma methotrexate concen­trations in patients with impaired renal function. The vertices of the triangle correspond to cellular/molecular (bottom left), animal (bottom right), and human (top) research.](1401fig3){#F3}

A further advantage of effective article-based metrics is that they can be validly extended to compare collections of articles. [Figure 4](#F4){ref-type="fig"} shows a real-world example of the use of article-based metrics to assess a large number of publications in two distinct but related areas of biomedical research---basic cell biology and neurological function. We randomly sampled 2000 NIH-funded articles from the 20 journals in which NIH investigators from these fields most frequently published their work between 2007 and 2012. As we showed recently, although practitioners in those fields do not have equal access to high-JIF journals ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} and [Figure 4A](#F4){ref-type="fig"}), the distribution of the respective article-level RCR values is statistically indistinguishable ([@B28]). This comparison is illustrated in treemaps of the randomly selected articles from [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Although there are a comparable number of highly influential articles in both areas of science (those in the top quintile, RCR \> 2.39; [Figure 4B](#F4){ref-type="fig"}), there is a striking difference in the extent to which the research exhibits direct translation to clinical trials or guidelines ([Figure 4C](#F4){ref-type="fig"}). Combining these measurements of I and T ([Figure 4D](#F4){ref-type="fig"}) shows just how poorly JIF represents the broadly disseminated contributions that typify progress in biomedical research.

![Comparison of I and T for NIH-funded articles in the areas of cell biology and neurological function from 2007 to 2012. These treemaps compare several metrics for the 20 journals in which NIH-funded cell biologists (left) and neurobiologists (right) publish their work most frequently. Each rectangle within the map represents one of the journals (numbered 1--20; see [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} for lists of the journals), and its size is proportional to the number of NIH-funded publications in that journal. The rectangles are shaded from light blue to dark blue, based on increasing values of the corresponding journal for four different metrics: (A) JIF, (B) number of articles with an RCR in the top quintile, (C) number of articles cited by a clinical trial or guideline, and (D) the sum of articles with an RCR in the top quintile and articles cited by a clinical trial or guideline. Relative values can be assessed by comparing the darkness of the blue shading. For example, rectangle 1 under Neurological function (representing the journal *NeuroImage*) has a relatively low JIF (light blue) but a relatively high number of publications with RCR in the top quintile (dark blue).](1401fig4){#F4}

###### 

Cell biology journals (2007--2012).

  Rank^a^   Journal                       Number of ­publications^b^   2012 JIF   Percentage of publications with RCR \> 2.39^c^   Percentage of publications cited by CT/CG^d^
  --------- ----------------------------- ---------------------------- ---------- ------------------------------------------------ ----------------------------------------------
  1         *J Biol Chem*                 341                          4.7        11.1                                             5.6
  2         *Proc Natl Acad Sci USA*      215                          9.7        34.4                                             7.4
  3         *Mol Biol Cell*               150                          4.8        11.3                                             6.0
  4         *PLoS One*                    141                          3.7        8.5                                              5.0
  5         *J Cell Biol*                 122                          10.8       35.2                                             5.7
  6         *Cell*                        109                          32.0       65.1                                             11.0
  7         *Curr Biol*                   106                          9.5        21.7                                             3.8
  8         *Dev Biol*                    95                           3.9        3.2                                              2.1
  9         *Development*                 95                           6.2        9.5                                              1.1
  10        *Mol Cell*                    78                           15.3       42.3                                             6.4
  11        *Dev Cell*                    70                           12.9       31.4                                             5.7
  12        *Science*                     64                           31.0       70.3                                             7.8
  13        *J Cell Sci*                  63                           5.9        11.1                                             6.3
  14        *Nature*                      63                           38.6       69.8                                             20.6
  15        *Nat Cell Biol*               53                           20.8       39.6                                             11.3
  16        *PLoS Genet*                  50                           8.5        10.0                                             2.0
  17        *Mol Cell Biol*               49                           5.4        18.4                                             10.2
  18        *Dev Dyn*                     48                           2.6        0.0                                              0.0
  19        *Invest Ophthalmol Vis Sci*   47                           3.4        14.9                                             23.4
  20        *Cell Cycle*                  41                           5.3        7.3                                              0.0

^a^Rank indicates the relative frequency with which NIH-funded cell biologists published their work in the given journal.

^b^Two thousand articles were randomly selected from among the NIH-funded cell biology articles in the given 20 journals.

^c^Number of articles in the top quintile of RCR values.

^d^Number of articles cited by a clinical trial (CT) or clinical guideline (CG).

###### 

Neurobiology journals (2007--2012).

  Rank^a^   Journal                       Number of publications^b^   2012 JIF   Percentage of publications with RCR \> 2.39^c^   Percentage of publications cited by CG/CT^d^
  --------- ----------------------------- --------------------------- ---------- ------------------------------------------------ ----------------------------------------------
  1         *NeuroImage*                  228                         6.3        39.5                                             54.4
  2         *J Neurosci*                  153                         6.9        53.6                                             62.7
  3         *Neuropsychologia*            133                         3.5        19.5                                             57.1
  4         *J Acoust Soc Am*             125                         1.6        11.2                                             18.4
  5         *Psychopharmacology (Berl)*   125                         4.1        20.8                                             47.2
  6         *PLoS One*                    115                         3.7        20.9                                             37.4
  7         *Biol Psychiatry*             111                         9.2        58.6                                             69.4
  8         *Cognition*                   99                          3.5        18.2                                             43.4
  9         *J Cogn Neurosci*             92                          4.5        31.5                                             52.2
  10        *Brain Res*                   90                          2.9        14.4                                             44.4
  11        *J Speech Lang Hear Res*      89                          2.0        13.5                                             34.8
  12        *J Neurophysiol*              85                          3.3        30.6                                             51.8
  13        *Psychol Sci*                 81                          4.5        38.3                                             56.8
  14        *Dev Sci*                     74                          3.6        33.8                                             51.4
  15        *Proc Natl Acad Sci U S A*    74                          9.7        59.5                                             64.9
  16        *Psychiatry Res*              73                          2.5        21.9                                             42.5
  17        *Neurology*                   71                          8.2        54.9                                             40.8
  18        *Cereb Cortex*                63                          6.8        52.4                                             69.8
  19        *Behav Brain Res*             62                          3.3        14.5                                             17.7
  20        *Exp Brain Res*               57                          2.2        7.0                                              40.4

^a^Rank indicates the relative frequency with which NIH-funded neurobiologists published their work in the given journal.

^b^Two thousand articles were randomly selected from among the NIH-funded neurobiology articles in the given 20 journals.

^c^Number of articles in the top quintile of RCR values.

^d^Number of articles cited by a clinical trial (CT) or clinical guideline (CG).

This analysis was repeated for all NIH-funded publications in 2012. Overall, as expected from our previous work ([@B28]), only 8% of the most influential PubMed articles in 2012 (top quintile, RCR \> 2.39) were published in high-profile journals (JIF ≥ 28). The treemaps in [Figure 5](#F5){ref-type="fig"} illustrate this for the journals ranked from 1st to 21st in terms of having published the most articles authored by NIH investigators in 2012 ([Table 3](#T3){ref-type="table"}). Again, the inadequacy of the JIF metric ([Figure 5A](#F5){ref-type="fig"}) as a way to represent the research that is either most influential ([Figure 5B](#F5){ref-type="fig"}) or directly translates into clinical work ([Figure 5C](#F5){ref-type="fig"}) is apparent. The data for three journals that published similar numbers of NIH-funded articles in 2012---*Clinical Cancer Research*, *Cell*, and *Science*---provide a revealing example. The combined number of influential and clinically relevant articles is comparable for all three journals ([Figure 5D](#F5){ref-type="fig"}), despite the approximately fourfold lower JIF of *Clinical Cancer Research* ([Table 3](#T3){ref-type="table"}). This modified approach therefore both balances the measurement of influence by doing so at the article level and appropriately credits the expected larger number of clinically relevant articles in the lower-JIF journal.

![Measuring I and T for all NIH-funded articles in 2012. Rectangles are as described in the [Figure 4](#F4){ref-type="fig"} legend. The number in each rectangle corresponds to the list of journals in [Table 3](#T3){ref-type="table"} (ranked by the relative frequency with which NIH-funded scientists published their work in that journal).](1401fig5){#F5}

###### 

All journals (2012).

  Rank^a^   Journal                       Total number of publications   JIF    Percentage of ­publications with RCR \> 2.39^b^   Percentage of ­publications cited by CG/CT^c^   Percentage I + T^d^
  --------- ----------------------------- ------------------------------ ------ ------------------------------------------------- ----------------------------------------------- ---------------------
  1         *PLoS One*                    4792                           3.7    10.9                                              12.5                                            23.4
  2         *J Biol Chem*                 1916                           4.7    12.9                                              5.2                                             18.1
  3         *Proc Natl Acad Sci USA*      1752                           9.7    36.4                                              13.1                                            49.5
  4         *J Neurosci*                  928                            6.9    30.4                                              15.1                                            45.5
  5         *J Virol*                     703                            5.1    14.8                                              10.8                                            25.6
  6         *Blood*                       697                            9.1    33.0                                              39.3                                            72.3
  7         *J Immunol.*                  695                            5.5    13.1                                              15.3                                            28.4
  8         *J Am Chem Soc*               685                            10.7   31.5                                              0.1                                             31.6
  9         *Biochemistry*                552                            3.4    6.7                                               1.1                                             7.8
  10        *Biochim Biophys Acta*        458                            4.4    23.1                                              7.9                                             31.0
  11        *NeuroImage*                  432                            6.9    38.9                                              35.2                                            74.1
  12        *Nature*                      430                            38.6   83.5                                              37.4                                            120.9
  13        *Nucleic Acids Res*           427                            8.3    24.6                                              5.4                                             30.0
  14        *Cancer Res*                  369                            8.7    32.0                                              23.3                                            55.3
  15        *Invest Ophthalmol Vis Sci*   366                            3.4    20.8                                              20.2                                            41.0
  16        *PLoS Genet*                  365                            8.5    19.2                                              7.7                                             26.9
  17        *Clin Cancer Res*             351                            7.8    33.9                                              45.3                                            79.2
  18        *Cell*                        347                            32.0   76.7                                              15.6                                            92.3
  19        *Science*                     341                            31.0   69.2                                              19.9                                            89.1
  20        *PLoS Pathog*                 313                            8.1    33.9                                              15.7                                            49.6
  21        *J Clin Invest*               284                            12.8   49.6                                              33.1                                            82.7

^a^Rank indicates the relative frequency with which NIH awardees published their work in the given journal.

^b^Number of articles in the top quintile of RCR values.

^c^Number of articles cited by a clinical trial (CT) or clinical guideline (CG).

^d^Number of articles of high influence (RCR \> 2.39; I) plus the number that exhibited direct translation (cited by a clinical trial or guideline; T). Note that a given publication may have high influence and a citation from a clinical trial or guideline, so percentage I + T can be \>100%.

USING THE SCIENTIFIC METHOD TO PROMOTE THE ADVANCEMENT OF SCIENCE
=================================================================

The goal of replacing journal-level with article-level assessments is actively being pursued at the NIH. Recent analyses conducted by the NIH Office of Extramural Research and the National Institute of General Medical Sciences have used the RCR method to measure outcomes of awarded grants ([@B21]; [@B20]; [@B34], [@B35]). The NIH will continue to promote the shift to article-level assessments in partnership with the scientific community, including collaborators at other domestic and international funding agencies, private foundations, and academic institutions, as part of an ongoing effort to implement data-driven decision making that improves the shared stewardship of research investments. Indeed, use of RCR has already spread outside of the NIH; the Wellcome Trust in the United Kingdom and Fondazione Telethon in Italy have now adopted RCR as part of their suite of portfolio analysis tools ([@B41]). Although the scope of this effort traverses the boundaries of biomedical research, the wisdom of the Hippocratic Oath provides a guiding principle: first, do no harm. When comparing portfolios of research investments, it is critical to ensure that those comparisons are "apples to apples." For example, as shown in [Figure 4](#F4){ref-type="fig"}, when measuring at the journal level, we get the wrong answer; although NIH-funded studies of neurological function and cell biology appear in two very different sets of journals, at the article level, one is at least as influential as the other. Similarly, the effectiveness of new funding initiatives cannot be properly analyzed without carefully determining the most appropriate methods and control groups. When samples sizes allow, propensity score matching should be used to eliminate confounding variables that can lead to erroneous conclusions. Another caveat is that, as is true for both clinical trials and preclinical research, these studies must be effectively powered by using sufficiently large sample sizes. Fortunately, improvements in computational methodology and database management now readily permit such large-scale analyses; calculation of RCR values for 24 million articles ([@B28]) took less than 1 day to complete. In short, the hallmarks of the scientific method, including due diligence in selecting the appropriate questions, methods, controls, and standards of analysis, are just as essential when attempting to analyze research portfolios and/or track scientific advances.

FUTURE DIRECTIONS
=================

This new area of research that can inform decision making, sometimes termed "science of science," is understandably of great interest to science funders and stakeholders alike. From the policy and program management perspective, it has the exciting potential to guide decisions by revealing overlapping investments, detecting emerging areas, and demarcating research gaps. In doing this work, it is essential not to lose sight of the fact that the most impactful advances in science, those that result in paradigm shifts ([@B31]), are by their very nature anecdotal, and the resulting ripple effects are difficult to track effectively. Indeed, effective tracking of what Kuhn called "normal science" has the potential to optimize the distribution of research investments in a way that increases the likelihood that paradigm-challenging research can flourish.

As founders of a new field of research that can take full advantage of the rapid proliferation of ever more sophisticated computational resources and methodologies, science-of-science scholars are poised to make seminal discoveries that at a minimum can reveal features of normal science and how it progresses. It is increasingly straightforward to develop new methods of analysis, build powerful algorithms, and share them globally. The quality of a wide variety of data fields, including research awards, publications, citations, patents, drugs, and devices, to name but a few, continues to improve, as does the interoperability of the databases and systems that house them. Stewards of research resources have a duty to explore the resulting new opportunities in support of data-driven decision making whenever strong evidence indicates that the use of such methodologies provides an undistorted lens through which to view research investments and the resulting productivity and/or impact. That said, there must be strong evidence that any new methodology has undergone the most rigorous testing to validate its capacity to distinguish between "fool's gold" and real discoveries. It is also crucial to implement such new tools wisely, understanding that no single metric or approach tells the whole story and using the outputs of science-of-science research only to supplement, never to replace, human judgment. The summative result of these efforts will be a bright future for the scientific enterprise as we strive together to optimize the rate of scientific discovery and demonstrate the value of investments in research and the resulting impact on human health and beyond.

DOI:[10.1091/mbc.E16-01-0037](http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E16-01-0037)

I thank Jim Anderson, Mike Lauer, Jon Lorsch, Kris Willis, and my colleagues in the Office of Portfolio Analysis for critical reading of the manuscript. I am also very grateful to all of my Office of Portfolio Analysis colleagues, both past and present, for their hard work and support, and in particular to Ian Hutchins for contributing [Figure 3](#F3){ref-type="fig"}, Ian and Aviva Litovitz for assistance in assembling the data sets underlying [Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}, and Rebecca Meseroll for helpful discussions.

CG

:   clinical guideline

CT

:   clinical trial

I

:   influence

JIF

:   Journal Impact Factor

NIH

:   National Institutes of Health

P

:   productivity

Q

:   quality

R

:   reproducibility

RA

:   reference article

RCR

:   Relative Citation Ratio

S

:   sharing of data

T

:   translation.
